Journal Reviews
Inverted internal limiting membrane flap vs internal limiting membrane insertion technique for large macular holes
This meta-analysis aimed to compare and evaluate the morphological and functional outcomes between the inverted internal limiting membrane (ILM) flap and ILM insertion techniques in the treatment of large macular holes (MHs). The primary outcome measures were defined by the...
Current concepts of the uveitis-glaucoma-hyphaema (UGH) syndrome
The authors discuss pathophysiology, aetiology and current management strategies of UGH syndrome. The clinical features of UGH are different than initial descriptions. UGH today is most often associated with posterior chamber IOLs that are not placed within the capsular bag...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
Bromfenac versus betamethasone in diabetic macular oedema
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
Macular measurements for amblyopic eyes
This study aimed to evaluate the macular parameters including foveal avascular zone (FAV) size and vessel density in amblyopia vs fellow eyes. The study included 23 unilateral amblyopia children (9.86 ±3.12 years; 52.2% female) and non-amblyopia control eyes (8.67 ±2.06...
Brolucizumab in age-related macular degeneration, HAWK Study
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Effect of heredity on risk of diabetic retinopathy
This study used survival analysis on 2199 patients who had reached vision-threatening diabetic retinopathy to investigate the contribution of heredity to diabetes together with other known risk factors for the development of either proliferative diabetic retinopathy (PDR) or diabetic macular...
Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection
This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...
Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...
Does religious fasting affect intraocular pressure or retinal parameters?
Nearly one billion Muslims fast every year during the month of Ramadan. Due to the difference between the lunar and solar calendars, religious fasting time can range from 11 to 17 hours per day. This prolonged abstinence from food and...
OCT findings after strabismus surgery for macular, choroidal and nerve fibre thickness
This study used OCT to investigate the changes in the central macular thickness, subfoveal choroidal thickness (SFCT) and retinal nerve fibre layer (RNFL) after horizontal rectus surgery for patients with strabismus. This was a retrospective study and patients were grouped...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
